presents
Wheeless' Textbook of Orthopaedics
www.wmt.com
Tracking Pixel

Snake Bite Wounds

- See: necrotizing fascitis

- Discussion:
    - snake bite resources
    - snake types:
         - pit vipers (crotaline) which include rattlesnakes, cottonmouths, and copperheads;
               - crotalus (rattlesnakes)
               - agkistrodon (copperheads, water moccasins)
               - micrurus (coral snakes)

- Epidemiology:
            - 15% of the approximately 3000 species of snakes worldwide are considered harmful to humans
            - 1998-2001 – AAPCC reports annual average 6000 snakebites
              2000 of which were from venomous snakes
            - true incidence - 7000-8000 bites by venomous snakes resulting in 5-6 deaths per year
            - eastern and western diamondback rattlesnakes account for most fatalities
            - Deaths typically in children, elderly, and those either not receiving antivenom,
              receiving antivenom after significant delay or inadequate quantities
            - Victims typically are male between 17-27 y.o.
            - 98% of bites are on the extremities
            - most bites occur between April and September
            - alcohol intoxication is a major factor (70%)

- Envenomation:
    - Implies that enough venom introduced to cause local or systemic signs
    - 25% of all pit viper bites are “dry”, 50% of all coral snake bites
    - Snake parts should not be handled directly, or handled with care– the bite reflex in recently killed/decapitated snakes remains intact
    - Definitive diagnosis requires positive identification of the snake and clinical manifestations of envenomation
    - 20% of snake bites in US are non-poisonous

- Pharmacology of Snake Bites:
    - Chemically complex mixture of proteins, peptides and enzymes
    - Designed to immobilize, kill, and digest prey
    - Highly stable – resistant to temp changes, drying, drugs
    - Bind to multiple receptor sites
    - Lethal components – smaller LMW polypeptides
    - Quantity, lethality and composition varies with species, age, geography, time of year
    - Damage to endothelial cells of vascular walls, causing blebs in the endothelium, dilating the perinuclear space, and breaking down the plasma membrane
    - Affect almost every organ system – esp. CV, heme, respiratory, nervous


- Work Up:
    - serial measurements of vital signs especially BP for minimum of 8 hours (note delayed response to venom);
    - laboratory data: a minority of patients will require pRBC transfusion, FFP, or even platlets;
         - H and H
         - platlet count
         - PT/PTT (need to rule out consumptive coagulopathy);
         - creatine kinase
         - urinalysis


- Dart Severity Scoring:
    - grade 0: no envenomation.  fang marks and minimal pain.
    - grade I:
          - minimal envenomation. fang marks, pain, 1 to 5 inches of edema and erythema in 1st 5 hours;
          - no systemic symptoms;
    - grade II:
          - moderate envenomation. fang marks, pain, 6-12 inches of edema in first 12 hours;
          - systemic symptoms may be present along with rapid progression of signs from grade I.
          - may have bleeding from bite site;
    - grade III:
          - severe envenomation. fang marks, pain, edema greater than 12 inches in first 12 hours.
          - systemic symptoms, including coagulation defects;
          - signs of grade I and II envenomation appear in rapid progression;
    - grade IV:
          - very severe envenomation.  local reaction develops rapidly.
          - edema may involve ipsilateral trunk. ecchymoses, necroses, and blebs develop.
          - potential for compartment syndrome;


- Treatment Considerations:
    - US national hotline: national hotline at 800-222-1222
    - bleeding disorders
    - compartment syndrome
    - infection
    - antivenom:
          - antivenoms are directed against two main groups: crotaline (pit vipors) and coral snakes
          - antivenom (CroFab; FabAV) composed of purified Fab specific to indigenous snake species
          - Fab molecules have a shorter half-life than IgG molecules and may allow recurrence of venom effects, if additional doses are not administered (systemic
                effects may reoccur hours or even days after treatment);
                - Fab preparation has produced fewer acute or delayed (serum sickness) allergic reactions;
          - indications for treatment:
                - most indicated for systemic symptoms, but in some cases, it may be used for rapidly advancing local symptoms;
                       - worsening local injury (eg, swelling, ecchymosis);
                       - clinically important coagulation abnormality, or systemic effects (eg, hypotension, altered mental status);
                - be aware that over use of antivenom will lead to cases of anaphylaxis;
                - antivenom is composed of purified Fab specific to indigenous snake species
                - Fab preparation has produced fewer acute or delayed (serum sickness) allergic reactions;
          - dosage: adequate dosage will reverse systemic effects (usually 8-12 vials);
          - complications:
                - anaphylaxis
                - overall rate of serum sickness after the administration of FabAV is about 15 percent;






Bacteriology of rattlesnake venom and implications for therapy.

Bacteriology of human and animal bite wounds.

The efficacy of tourniquets as a first-aid measure for Russell's viper bites in Burma.

Tourniquet application after cobra bite: delay in the onset of neurotoxicity and the dangers of sudden release.

Crotalid Envenomation:  The Southern Arizona Experience.  JT. Tokish et al.  Jour. Orthop Trauma.  Vol 15. No 1. p 5-9.

Rattlesnake Bites in Children:Antivenin Treatment and Surgical Indications

Initial Experience with Crotalidae Polyvalent Immune Fab (Ovine) Antivenom in the Treatment of Copperhead Snakebite Lavonas et al. Ann Emerg Med. 2004:43:200-206.

Pediatric snakebites: lessons learned from 114 cases











Original Text by Clifford R. Wheeless, III, MD.

Last updated by Clifford R. Wheeless, III, MD on Friday, September 5, 2008 9:55 pm